Genetic aspects of smoking and impact on clinical care;Aspects génétiques de la consommation de tabac et prise en charge clinique

Revue Medicale Suisse

Volumn 5, Issue 210, 2009, Pages 1463-1467

  Dobrinas, Maria ^a   Cornuz, Jacques ^c   Kohler Serra, Myriam ^c   Puhl, Michael ^c   Eap, Chin B ^b  

^a Hopital de Cery   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CIGARETTE SMOKING; DRUG METABOLISM; ENZYME ANALYSIS; GENETIC ANALYSIS; HEREDITY; HUMAN; MEDICAL CARE; PUBLIC HEALTH; REVIEW; SMOKING CESSATION PROGRAM; TOBACCO DEPENDENCE;

GANGLIONIC STIMULANTS; HUMANS; NICOTINE; RECEPTORS, NICOTINIC; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 68149170808     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Office fédéral de la statistique NS. Enquête suisse sur la santé,1997. None Specified 1999.
2. US Public health service. Smoking and health. Report of the advisory commitee to the surgeon general of the public health service. US Department of Health, Education and Welfare, Public Health Service, center for disease control. PHS publication 1964;1103.
3. * Berrettini WH, Lerman CE. Pharmacotherapy and pharmacogenetics of nicotine dependence. Am J Psychiatry 2005;162:1441-1451
4. Faber MS, Jetter A, Fuhr U. Assessment of CYPIA2 activity in clinical practice: Why, how, and when? Basic Clin Pharmacol Toxicol 2005;97:125-134
5. Heath AC, Martin NG. Genetics models for the natural history of smoking: Evidence for a genetic influence on smoking persistence. Addict Behav 1993;18:19-34.
6. ** Benowitz NL. Clinical pharmacology of nicotine: Implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008;83:531-41.
7. Nakajima M, Kwon JT, Tanaka N, et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001;68:72-78 (Pubitemid 32108674)
8. Inoue K, Yamazaki H, Shimada T. CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians. Arch Toxicol 2000;73:532-539 (Pubitemid 30062484)
9. Fukami T, Nakajima M, Yoshida R, et al. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 2004;76:519-527 (Pubitemid 39601542)
10. * Benowitz NL, Swan GE, Jacob P III, et al. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 2006;80:457-467
11. Ando M, Hamajima N, Ariyoshi N, et al. Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults. J Epidemiol 2003;13:176-181 (Pubitemid 44143818)
12. Schoedel KA, Hoffmann EB, Rao Y, et al. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004;14:615-626 (Pubitemid 39281816)
13. * Lerman C, Tyndale R, Patterson F, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006;79:600-608
14. Mwenifumbo JC, Lessov-Schlaggar CN, Zhou Q, et al. Identification of novel CYP2A6*1B variants: The CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther 2008;83:115-21.
15. Fukami T, Nakajima M, Yamanaka H, et al. A novel duplication type of CYP2A6 gene in African-American population. Drug Metab Dispos 2007;35:515-520 (Pubitemid 46513277)
16. Feng Y, Niu T, Xing H, et al. A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet 2004;75:112-121 (Pubitemid 38801907)
17. * David SP, Munafo MR. Genetic variation in the dopamine pathway and smoking cessation. Pharmacogenomics 2008;9:1307-1321
18. Munafo M, Clark T, Johnstone E, et al. The genetic basis for smoking behavior: A systematic review and meta-analysis. Nicotine Tob Res 2004;6:583-597 (Pubitemid 39248145)
19. Comings DE, Ferry L, Bradshaw-Robinson S, et al. The dopamine D2 receptor (DRD2) gene: A genetic risk factor in smoking. Pharmacogenetics 1996;6:73-79 (Pubitemid 26096751)
20. Johnstone EC, Elliot KM, David SP, et al. Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 2007;16:1065-1069
21. O'Gara C, Stapleton J, Sutherland G, et al. Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment Pharmacogenet Genomics 2007;17:61-67
22. Eap CB, Bender S, Jaquenoud Sirot E, et al. Non-response to clozapine and ultrarapid CYP1A2 activity: Clinical data and analysis of the CYP1A2 gene. J Clin Psychopharmacol 2004;24:214-219 (Pubitemid 38380846)
23. Bondolfi G, Morel F, Crettol S, et al. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005;27:539-543 (Pubitemid 41098833)
24. Van Der Weide J, Steijns LS, Van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003;13:169-172 (Pubitemid 36324246)
25. Gardner MJ, Tornatore KM, Jusko WJ, et al. Effects of tobacco smoking and oral contraceptive use on theophylline disposition. Br J Clin Pharmacol 1983;16:271-80.
26. Fric M, Pfuhlmann B, Laux G, et al. The influence of smoking on the serum level of duloxetine. Pharmacopsychiatry 2008;41:151-155
27. Brownlowe K, Sola C. Clozapine toxicity in smoking cessation and with ciprofloxacin. Psychosomatics 2008;49:176.
28. * Zullino DF, Delessert D, Eap CB, et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002;17:141-143
29. De Leon J, Diaz FJ, Rogers T, et al. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr Res 2002;56:47-54. (Pubitemid 34655467)
30. Landi MT, Sinha R, Lang NP, et al. Human cytochrome P4501A2. In: Ryder W, editor. Metabolic polymorphisms and susceptibility to cancer. International agency for research on cancer (Lyon, France) scientific publications 1999;148:173-195
31. Murayama N, Soyama A, Saito Y, et al. Six novel nonsynonymous CYP1A2 gene polymorphisms: Catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 2004;308:300-306 (Pubitemid 38090731)
32. Sachse C, Brockmoller J, Bauer S, et al. Functional significance of a C → A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-449 (Pubitemid 29161279)
33. * Patterson F, Schnoll R, Wileyto E, et al. Toward personalized therapy for smoking cessation: A randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008;84:320-325
34. Choong E, Solida A, Lechaire C, et al. Suivi du syndrome métabolique induit par les antipsychotiques atypiques: recommandations et perspectives pharmacogénétiques. Rev Med Suisse 2008;4:1994-1999
35. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999;36:425-438
36. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: A pharmacokinetic perspective. CNS Drugs 2001;15:469-494 (Pubitemid 32601905)
37. ** Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004;76:178-184